Get the Daily Brief
Latest Biotech News
FDA again rebuffs Atara’s cell therapy... company calls agency reversal a 'complete reversal'
The FDA issued another rejection for Atara Biotherapeutics’ allogeneic T‑cell therapy tabelecleucel (Ebvallo) for EBV‑positive post‑transplant lymphoproliferative disease, reversing prior agency...
WGS classifier finds HRD missed by standard tests: pan‑cancer study
A pan‑cancer study from Weill Cornell Medicine, Illumina and NewYork‑Presbyterian used whole‑genome sequencing (WGS) and an Isabl‑derived classifier to detect homologous recombination deficiency...
Bioprocess bets: Charles River buys PathoQuest and K.F.; Asimov licenses LV Edge to AGC
Charles River Laboratories exercised its option to acquire the remaining 79% of PathoQuest and agreed to buy assets of K.F. (Cambodia) to strengthen NGS‑based biologics QC and nonhuman primate...
Tahoe, Arc Institute and Biohub fund massive virtual‑cell dataset: 120M+ perturbations
Tahoe Therapeutics, the Arc Institute and Biohub committed multimillion‑dollar funding to generate a large, perturbation‑heavy single‑cell dataset to support virtual cell models. Tahoe will...
AbbVie buys PD‑1/VEGF bispecific: $650m upfront
AbbVie agreed to acquire ex‑China rights to RemeGen’s RC148, a PD‑1/VEGF‑targeted bispecific antibody, in a licensing deal that includes a $650 million upfront payment and up to $4.95 billion in...
Nvidia and Lilly put $1bn on the table: AI lab for drug discovery
Nvidia and Eli Lilly announced a five‑year, up‑to‑$1 billion co‑investment to create an AI drug‑discovery laboratory in San Francisco. Lilly will supply biological data and drug discovery...
Illumina unveils billion‑cell atlas... pharma signs on
Illumina launched a perturbation‑heavy single‑cell dataset it calls the Billion Cell Atlas and is offering the resource to pharmaceutical partners to fast‑track target validation and train AI...
Tahoe, Arc and Biohub build public virtual‑cell perturbation atlas
Tahoe Therapeutics, the Arc Institute and the Biohub committed multimillion‑dollar funding to build a public, perturbation‑heavy single‑cell dataset intended to accelerate virtual cell model...
Soley raises $200m Series C – advances stress‑sensing drug pipeline
Soley Therapeutics closed a $200 million Series C to move its stress‑sensing drug candidates into late‑stage development, with a focus on oncology, neurodegeneration and metabolic disease....
Tessera restructures after Regeneron tie‑up; advances AATD gene‑editing trial
Tessera Therapeutics announced a workforce reduction of about 35% as it shifts priorities around a collaboration with Regeneron that includes a $150 million investment to develop a gene‑editing...
10x Genomics pushes clinical playbook – CLIA lab, partnerships and testing growth
10x Genomics announced three clinical‑focused collaborations and plans to open a CLIA‑certified lab in early 2027 to accelerate adoption of single‑cell and spatial assays in oncology and...
Basecamp’s EDEN AI designs insertable gene sequences: programmable insertion
Basecamp Research disclosed EDEN, an evolutionary AI family that designed AI‑generated enzymes enabling programmable insertion of large therapeutic DNA sequences at precise genome locations. The...
Novartis pays $165m for SciNeuro brain‑shuttle; big‑ticket milestones possible
Novartis licensed a preclinical amyloid‑targeting brain‑shuttle program from SciNeuro for $165 million upfront with as much as $1.5 billion in additional milestones. The collaboration aims to...
Asimov licenses LV Edge to AGC Biologics – simplifies lentiviral manufacturing
Asimov and AGC Biologics struck a licensing deal to deploy Asimov’s LV Edge Packaging cell line at AGC’s Milan Cell & Gene Center of Excellence. The LV Edge system uses an engineered HEK293 line...
AbbVie pays $650M upfront for PD-1/VEGF asset — Global rights ex‑China
AbbVie announced an exclusive licensing deal with China’s RemeGen to develop, manufacture and commercialize RC148, a PD‑1/VEGF bispecific antibody. AbbVie paid $650 million up front and can...
Lilly and Nvidia commit $1B to AI drug‑discovery lab — five‑year pact
Eli Lilly and Nvidia announced a five‑year, up to $1 billion collaboration to build a San Francisco AI laboratory focused on accelerating drug discovery. The partnership combines Lilly’s...
Illumina unveils Billion Cell Atlas; Tahoe joins large single‑cell push
Illumina launched its Billion Cell Atlas initiative, releasing massive single‑cell perturbation data across ~200 cell lines and aiming for one billion cells by year‑end. The company said the atlas...
AI designs programmable gene insertion — Basecamp’s EDEN demonstrates breadth
Basecamp Research said its EDEN family of evolutionary AI models can design therapeutic molecules that enable programmable insertion of large DNA sequences into precise genomic locations across...
FDA eases manufacturing oversight for cell and gene therapies — CBER guidance
The U.S. Food and Drug Administration outlined steps to relax and modernize manufacturing and quality expectations for cell and gene therapies, signaling increased regulatory flexibility to...
Large raises and funds: Parabilis nets $305M; Arkin closes $100M early‑stage fund
Parabilis Medicines closed a $305 million Series F to advance zolucatetide (FOG‑001) toward Phase III for desmoid tumors; the company said the financing sparked IPO speculation. Parabilis...